Validation and Application of the Chinese Version of the M. D. Anderson Symptom Inventory in Breast Cancer Patients

Abstract

Objective

To validate and use the Chinese Version of the M. D. Anderson Symptom Inventory (MDASI-C) to assess the symptom burden of breast cancer patients in China.

Methods

A total of 342 breast cancer patients in China participated in this study. Their symptoms were investigated with the MDASI-C from November 2020 to February 2021, and the reliability and validity of this tool were evaluated, respectively. Cluster analysis and correlation analysis were also performed.

Results

The Cronbach’s alpha coefficient values of the symptom and interference items were 0.827 and 0.880, respectively. Construct validity revealed a four-factor structure. The Kaiser—Meyer—Olkin value was 0.760. The Karnofsky Performance Status, treatment phase, and cancer stage of the patients were grouped, and the differences of scores within the groups were significant. In addition, the employment status, education level, and age of the patients were significantly correlated with the symptoms. The correlation analysis of the education level of the patients showed that most of the symptoms and interference items were reduced as the education level was increased. The top three symptoms were disturbed sleep (3.10±2.52), difficulty remembering (2.54±2.30), and fatigue (2.24±2.13). The clinical and biochemical indicators such as body mass index and neutral granulocyte lymphocyte ratio had effects on many symptoms. As the patients’ BMI increased, the patients’ pain, disturbed sleep, and difficulty remembering were aggravated, and numbness was alleviated.

Conclusion

The MDASI-C is a reliable and effective assessment tool to evaluate patients with breast cancer in China. The symptoms are related to many clinical and biochemical indicators.

Keywords

M. D. Anderson Symptom Inventory / breast cancer / validation / application / quality of life

References

[1] SiegelRL, MillerKD, FuchsHE, et al.. Cancer Statistics, 2021. CA Cancer J Clin, 2021, 71(1): 7-33

[2] AzimHA, IbrahimAS. Breast cancer in Egypt, China and Chinese: statistics and beyond. J Thorac Dis, 2014, 6(7): 864-866

[3] CaoW, ChenHD, YuYW, et al.. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl), 2021, 134(7): 783-791

[4] KalterJ, Verdonck-de LeeuwIM, et al.. Effects and moderators of psychosocial interventions on quality of life, and emotional and social function in patients with cancer: An individual patient data meta-analysis of 22 RCTs. Psychooncology, 2018, 27(4): 1150-1161

[5] SubramaniamS, KongYC, ChinnaK, et al.. Health-related quality of life and psychological distress among cancer survivors in a middle-income country. Psychooncology, 2018, 27(9): 2172-2179

[6] WenFH, ChenJS, ChouWC, et al.. Quality of life and psychological distress are differentially associated with distinct symptom-functional states in terminally ill cancer patients’ last year of life. Psychooncology, 2018, 27(9): 2111-2118

[7] PachmanDR, BartonDL, SwetzKM, et al.. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol, 2012, 30(30): 3687-3696

[8] PandyaC, MagnusonA, DaleW, et al.. Association of falls with health-related quality of life (HRQOL) in older cancer survivors: A population based study. J Geriatr Oncol, 2016, 7(3): 201-210

[9] ShapiroCL. Cancer Survivorship. N Engl J Med, 2018, 379(25): 2438-2450

[10] HamerJ, McDonaldR, ZhangL, et al.. Quality of life (QOL) and symptom burden (SB) in patients with breast cancer. Support Care Cancer, 2017, 25(2): 409-419

[11] AdmiraalJM, van NuenenFM, BurgerhofJG, et al.. Cancer patients’ referral wish: effects of distress, problems, socio-demographic and illness-related variables and social support sufficiency. Psychooncology, 2016, 25(11): 1363-1370

[12] ParkEM, DealAM, CheckDK, et al.. Parenting concerns, quality of life, and psychological distress in patients with advanced cancer. Psychooncology, 2016, 25(8): 942-948

[13] SaadatpourL, HematiS, HabibiF, et al.. Linguistic Validation of the M. D. Anderson Symptom Inventory in Persian-Speaking Iranian Cancer Patients. J Pain Symptom Manage, 2015, 50(3): 387-393

[14] MendozaTR, ZhaoF, CleelandCS, et al.. The validity and utility of the M. D. Anderson Symptom Inventory in patients with breast cancer: evidence from the symptom outcomes and practice patterns data from the eastern cooperative oncology group. Clin Breast Cancer, 2013, 13(5): 325-334

[15] WangXS, WangY, GuoH, et al.. Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients. Cancer, 2004, 101(8): 1890-1901

[16] WangXS, CleelandCS, MendozaTR, et al.. Impact of cultural and linguistic factors on symptom reporting by patients with cancer. J Natl Cancer Inst, 2010, 102(10): 732-738

[17] AnshaboAT, MigbaruS, MuluA, et al.. Validation of the Amharic Version of the M. D. Anderson Symptom Inventory and Assessment of Symptoms in Ethiopian Cancer Patients. J Pain Symptom Manage, 2016, 51(5): 947-953

[18] GuirimandF, BuyckJF, Lauwers-AllotE, et al.. Cancer-related symptom assessment in France: validation of the French M. D. Anderson Symptom Inventory. J Pain Symptom Manage, 2010, 39(4): 721-733

[19] MystakidouK, CleelandC, TsilikaE, et al.. Greek M.D. Anderson Symptom Inventory: validation and utility in cancer patients. Oncology, 2004, 67(3–4): 203-210

[20] ChenRW, YangSL, XuZY, et al.. Validation and Application of the Chinese Version of the M. D. Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI-GI-C). J Pain Symptom Manage, 2019, 57(4): 820-827

[21] LinCC, ChangAP, CleelandCS, et al.. Taiwanese version of the M. D. Anderson symptom inventory: symptom assessment in cancer patients. J Pain Symptom Manage, 2007, 33(2): 180-188

[22] AktasA, WalshD, KirkovaJ. The psychometric properties of cancer multisymptom assessment instruments: a clinical review. Support Care Cancer, 2015, 23(7): 2189-2202

[23] CarvalhoCS, SouzaDS, LopesJR, et al.. Relationship between patient-generated subjective global assessment and survival in patients in palliative care. Ann Palliat Med, 2017, 6(Suppl 1): S4-S12

[24] GulatiRR. The Challenge of Cancer Pain Assessment. Ulster Med J, 2021, 90(1): 37-40

[25] LesleyA, HensonM, Matthew MaddocksP, et al.. Palliative care and the management of common distressing symptoms in advanced cancer: Pain, breathlessness, nausea and vomiting, and fatigue. J Clin Oncol, 2020, 38(9): 905-914

[26] CheungWY, LeLW, GaglieseL, et al.. Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer. Support Care Cancer, 2011, 19(3): 417-423

[27] NippRD, GreerJA, El-JawahriA, et al.. Age and Gender Moderate the Impact of Early Palliative Care in Metastatic Non-Small Cell Lung Cancer. Oncologist, 2016, 21(1): 119-126

[28] ChowE, AbdolellM, PanzarellaT, et al.. Predictive model for survival in patients with advanced cancer. J Clin Oncol, 2008, 26(36): 5863-5869

[29] ChowS, WanBA, PidduckW, et al.. Symptom clusters in patients with breast cancer receiving radiation therapy. Eur J Oncol Nurs, 2019, 42: 14-20

[30] SullivanCW, LeutwylerH, DunnLB, et al.. Stability of Symptom Clusters in Patients With Breast Cancer Receiving Chemotherapy. J Pain Symptom Manage, 2018, 55(1): 39-55

[31] RhondaliW, ChisholmGB, DaneshmandM, et al.. Association between body image dissatisfaction and weight loss among patients with advanced cancer and their caregivers: a preliminary report. J Pain Symptom Manage, 2013, 45(6): 1039-1049

[32] HwangSS, ChangVT, RueM, et al.. Multidimensional independent predictors of cancer-related fatigue. J Pain Symptom Manage, 2003, 26(1): 604-614

[33] StrasserF, BlumD, von MoosR, et al.. The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06). Ann Oncol, 2016, 27(2): 324-332